课题基金 / 基金详情

Role and Mechanisms of VAV1 alterations in Peripheral T-cell Lymphomas

Role and Mechanisms of VAV1 alterations in Peripheral T-cell Lymphomas
VAV1 改变在外周 T 细胞淋巴瘤中的作用和机制
批准号:
10317831
负责人:
Teresa Palomero
金额:
$37.06万
依托单位国家:
美国
项目类别:
财政年份:
2021
资助国家:
美国
项目状态:
未结题
起止时间:
2021-07-01 至 2026-05-31
关键词:
Adaptor Signaling ProteinAddressAffectAllelesAutomobile DrivingC-terminalCD4 Positive T LymphocytesCandidate Disease GeneCell CompartmentationCellsClonal ExpansionCytokine SignalingCytoskeletal ModelingDNA Sequence AlterationDevelopmentDiagnosisDisease ProgressionGATA3 geneGenetic TranscriptionGenetically Engineered MouseGenomicsGoalsGuanine Nucleotide Exchange FactorsHistologyHumanImmune EvasionInvestigational TherapiesKnock-in MouseLeadLymphomaLymphomagenesisMAP Kinase GeneMAPK8 geneMalignant - descriptorMediatingMedical GeneticsMusMutationMutation AnalysisNon-Hodgkin&aposs LymphomaOncogenesOncogenicPathogenesisPathogenicityPathologicPathway interactionsPatternPeripheralPharmacotherapyPoint MutationPre-Clinical ModelPrognosisProtein Tyrosine KinaseProto-OncogenesRHOA geneReceptor ActivationRecurrenceRoleS100A7Signal PathwaySignal TransductionSpecific qualifier valueStructure of germinal center of lymph nodeT cell differentiationT-Cell ActivationT-Cell LymphomaT-Cell ProliferationT-Cell ReceptorT-Cell TransformationT-LymphocyteTertiary Protein StructureTestingTherapeuticTumor Suppressor GenesTumor Suppressor ProteinsVAV1 genecell motilitycytokinehematopoietic tissuehigh riskin vivoindividualized medicineinsertion/deletion mutationinsightmigrationmolecular pathologymouse modelnovelnovel therapeuticsnuclear factors of activated T-cellspolarized cellpremalignantprogramsresponsetargeted sequencingtargeted treatmenttherapeutic targettooltranscriptome sequencingtumortumor initiationtumor-immune system interactions

项目摘要

项目成果

Teresa Palomero的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Project Summary/Abstract Peripheral T-cell lymphomas (PTCLs) represent a heterogeneous and poorly understood pathological group of non-Hodgkin lymphomas associated with poor prognosis. Despite major progress in recent years in the identification of genomic drivers in PTCL, understanding their mechanisms of transformation and identifying therapeutic targets remain a high priority in the field. Recently we have identified novel genetic alterations in the VAV1 oncogene in PTCL using a combination of RNAseq analysis and targeted sequencing of candidate genes. Most VAV1 genomic alterations are fusions and small intragenic deletions affecting the C-terminal domain of the protein. Our central hypothesis is that the VAV1 alterations lead to increase activation of signaling pathways downstream of VAV1 and act as oncogenic drivers of PTCL. Our preliminary results demonstrate that expression of the recurrent Vav1-myo1f fusion induces lymphomas that recapitulate the histology and molecular pathology of high-risk PTCL. The goals of this project are to characterize the mechanisms by which VAV1-MYO1F fusion promotes lymphomagenesis in vivo and to explore emerging specific therapeutic vulnerabilities in PTCL preclinical models.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
The role of PHF6 in the control of hematopoietic stem cell aging.
Role and Mechanisms of VAV1 alterations in Peripheral T-cell Lymphomas
Role and Mechanisms of VAV1 alterations in Peripheral T-cell Lymphomas
The role of PHF6 in the control of hematopoietic stem cell aging.
海外基金